Outcome and Prognostic Factors in Olfactory Neuroblastoma: A Rare Cancer Network Study

Ozşahin, Mahmut; Gruber, Guenther; Olszyk, O.; Karakoyun-Çelik, Ömür; Pehlivan, Berrin; Azria, D.; Roelandts, Martine; Kaanders, Johannes H.A.M.; Cengiz, Mustafa; Krengli, Marco; Matzinger, Oscar; Zouhair, Abderrahim

doi:10.1016/j.ijrobp.2009.09.019

Cited by 94 publications

(98 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies have identified the Kadish system, T staging of Dulguerov-Calcaterra, tumor grade, nodal involvement, and radiation dose to also be factors. 3,4,11 In this study, multivariable Cox regression analysis revealed advanced age, tumor grade, and modified Kadish stage to be negative independent predictors of OS, while female sex independently predicted better OS. The effect of age and sex on all-cause survival is expected in this analysis because the OS rate includes extraneous deaths from expected age-related mortality.…”

Section: Discussionmentioning

confidence: 53%

“…These findings agree with prior published studies. [3][4][5] Pathologic grading of ONB is by Hyams criteria, which groups tumors on a scale of I to IV based on histologic features that roughly represent a spectrum of benign to malignant behavior. Briefly, Hyams grade I tumors display preserved lobular architecture, zero mitotic index, no nuclear polymorphisms, prominent fibrillary matrix, no evidence of necrosis, and cells loosely organized around a central fibrillar eosinophilic material (Homer-Wright pseudorosettes).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Importance of Tumor Grade in Esthesioneuroblastoma Survival

Tajudeen

Arshi

Suh

et al. 2014

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Here, to our knowledge, we report the largest study investigating prognostic factors for survival, with the inclusion of tumor grade, in patients diagnosed with esthesioneuroblastoma. Patients with high-grade tumors had substantially worse survival rates than patients with low-grade tumors. Multivariable analysis revealed only receiving surgery as an independent predictor of disease-specific survival for patients with low-grade tumors, while modified Kadish stage and postoperative radiation therapy were significant factors in predicting disease-specific survival in patients with high-grade tumors. This study highlights the growing evidence that tumor grade should be a key factor in predicting survival in patients with esthesioneuroblastoma, and that adjuvant radiation therapy improves survival rates among patients with high-grade, but not low-grade, tumors.

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Importance of Tumor Grade in Esthesioneuroblastoma Survival

Tajudeen

Arshi

Suh

et al. 2014

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…Interestingly, it should be noted that unlike regional or distant failures, which most often occur within one year of treatment completion, local failure in EN can happen many years after treatment. The median time to local recurrence across multiple series ranges from a median of 50-60 months [24,[30][31][32][33].…”

Section: Fig 2 Time To Event Outcomesmentioning

confidence: 99%

“…The two cases of grade 2 retinopathy also occurred in patients where disease was in close proximity to the retina (<3 mm). Retinopathy has been documented at doses as low as [30][31][32][33][34][35] Gy, but rises exponentially as the dose increases above 50 Gy [41,42]. Concurrent and sequential use of chemotherapy, especially potential radiosensitizers like cisplatin, are also likely to play a role in the development of optic toxicity, though data regarding toxicity is limited.…”

Section: Fig 2 Time To Event Outcomesmentioning

confidence: 99%

Proton therapy for pediatric and adolescent esthesioneuroblastoma

Lucas

Ladra

MacDonald³

et al. 2015

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…This is supported by several studies that demonstrated superior outcomes for this combined approach when compared to just undergoing surgery or radiotherapy alone [9,[21][22][23][24][25][26][27][28][29][30] . In the meta-analysis by Dulguerov et al [3] , patients treated by surgery and radiotherapy had a 5y-OS of 65%.…”

Section: Discussionmentioning

confidence: 68%

Esthesioneuroblastoma: A case with prolonged disease control

et al. 2016

View full text Add to dashboard Cite

Esthesioneuroblastoma, a rare tumor arising from the olfactory vault, varies from being indolent to extremely aggressive. Owing to its rarity, the diagnosis, staging, and treatment of the disease are not well defined. According to a number of small observational retrospective studies and case reports, the disease's actual treatment involves surgery, radiotherapy, and/or chemotherapy (either as a single treatment or used in combination), depending on the disease's staging. Optimal treatment has not been standardized, particularly regarding the role of chemotherapy. We describe a case of advanced esthesioneuroblastoma with prolonged disease control, subjected to a multimodal therapy with surgery, radiotherapy, and chemotherapy, illustrating the benefits of this approach in managing a patient with esthesioneuroblastoma. Herein, we analyze the most important and controversial issues of this type of neoplasia.Keywords: esthesioneuroblastoma; nasal cavity; surgery; radiotherapy; chemotherapy

show abstract

Outcome and Prognostic Factors in Olfactory Neuroblastoma: A Rare Cancer Network Study

Cited by 94 publications

References 34 publications

Importance of Tumor Grade in Esthesioneuroblastoma Survival

Importance of Tumor Grade in Esthesioneuroblastoma Survival

Proton therapy for pediatric and adolescent esthesioneuroblastoma

Esthesioneuroblastoma: A case with prolonged disease control

Contact Info

Product

Resources

About